Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Hamid Namazi. (2012) Letter to the Editor. Current Medical Research and Opinion 28:11, pages 1755-1755.
Read now
Read now
Articles from other publishers (34)
Jin-Hyeon Hwang, Yu-Seong Park, Hyuk-Soon Kim, Dong-ha Kim, Sang-Hoon Lee, Chan-Hyeong Lee, Seung-Hoon Lee, Jung-Eun Kim, Sangkyu Lee, Ho Min Kim, Hyun-Woo Kim, Jihoon Kim, Wonhyo Seo, Hyo-Jung Kwon, Byoung-Joon Song, Do-Kyun Kim, Moon-Chang Baek & Young-Eun Cho. (2023) Yam-derived exosome-like nanovesicles stimulate osteoblast formation and prevent osteoporosis in mice. Journal of Controlled Release 355, pages 184-198.
Crossref
Crossref
Bryan Kuo, Alison Koransky & Cherie Lisa Vaz Wicks. (2023) Adrenal Crisis as An Adverse Reaction to Zoledronic Acid in a Patient With Primary Adrenal Insufficiency: A Case Report and Literature Review. AACE Clinical Case Reports 9:2, pages 32-34.
Crossref
Crossref
Bahri Ahmed, Issam Alkhouri, Ahmad Albassal & Asaad Shehada. (2023) An Evaluation of the Effectiveness of Local Delivery of Zoledronic Acid in Accelerating Bone Healing After the Extraction of Mandibular Third Molars. Cureus.
Crossref
Crossref
Dilek Ozge Zincir Ercin & Dogan Ercin. (2022) Evaluation of intravenous zoledronic acid-induced acute-phase response in the emergency department. Journal of Surgery and Medicine 6:8, pages 772-777.
Crossref
Crossref
K. Liepe, I. Murray & G. Flux. (2022) Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases. Seminars in Nuclear Medicine 52:2, pages 178-190.
Crossref
Crossref
E. V. Biryukova & M. V. Shinkin. (2022) Men’s health and osteoporosis: modern treatment and prevention options. Meditsinskiy sovet = Medical Council:21-1, pages 120-129.
Crossref
Crossref
Alberto Bongiovanni, Flavia Foca, Jessica Menis, Stefania Luigia Stucci, Fabrizio Artioli, Valentina Guadalupi, Maria Rosachiara Forcignanò, Manuela Fantini, Federica Recine, Laura Mercatali, Chiara Spadazzi, Marco Angelo Burgio, Valentina Fausti, Anna Miserocchi & Toni Ibrahim. (2021) Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Frontiers in Immunology 12.
Crossref
Crossref
René Fernández, Elisabeth Eppard, Wencke Lehnert, Luis David Jiménez-Franco, Cristian Soza-Ried, Matías Ceballos, Jessica Ribbeck, Andreas Kluge, Frank Rösch, Marian Meckel, Konstantin Zhernosekov, Vasko Kramer & Horacio Amaral. (2021)
Evaluation of Safety and Dosimetry of
177
Lu-DOTA-ZOL for Therapy of Bone Metastases
. Journal of Nuclear Medicine 62:8, pages 1126-1132.
Crossref
Crossref
Luca Dalle Carbonare, Monica Mottes & Maria Teresa Valenti. (2021) Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency. Nutrients 13:2, pages 561.
Crossref
Crossref
Xinlong Zang, Jingyi Zhou, Xiaoxu Zhang, Dawei Chen, Yantao Han & Xuehong Chen. (2021) Dual-targeting tumor cells and tumor associated macrophages with lipid coated calcium zoledronate for enhanced lung cancer chemoimmunotherapy. International Journal of Pharmaceutics 594, pages 120174.
Crossref
Crossref
Ahmad Oryan & Sonia Sahvieh. (2021) Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life Sciences 264, pages 118681.
Crossref
Crossref
Nobukazu Okimoto, Akinori Sakai, Toru Yoshioka, Tomohiro Kobayashi, Kei Asano, Shojiro Akahoshi, Toru Ishikura, Shito Fukuhara, Yoshifumi Fuse, Toshiyuki Mizuno, Yuji Katae, Hidehiro Matsumoto, Takayuki Ogawa, Shigeki Nishida, Satoshi Ikeda, Kunitaka Menuki, Jun Saito, Yuichi Okazaki, Naoyuki Mizuno & Saeko Fujiwara. (2019) Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. Journal of Bone and Mineral Metabolism 38:2, pages 230-239.
Crossref
Crossref
Remzi Bahşi, Volkan Atmiş, Tuğba Turgut, Deniz Mut Sürmeli, Çağlar Coşarderelioğlu, Hande Selvi Öztorun, Ahmet Yalçin, Sevgi Aras & Murat Varli. (2019) May zoledronic acid have negative effects on cognition and muscle performance?. Irish Journal of Medical Science (1971 -) 189:1, pages 191-196.
Crossref
Crossref
Deepak Kumar Khajuria, Ramakrishna Vasireddi, Manish Kumar Priydarshi & Debiprosad Roy Mahapatra. (2019) Ionic Diffusion and Drug Release Behavior of Core–Shell-Functionalized Alginate–Chitosan-Based Hydrogel. ACS Omega 5:1, pages 758-765.
Crossref
Crossref
Deepak Bushan Raina, David Larsson, Erdem Aras Sezgin, Hanna Isaksson, Magnus Tägil & Lars Lidgren. (2019) Biomodulation of an implant for enhanced bone-implant anchorage. Acta Biomaterialia 96, pages 619-630.
Crossref
Crossref
Ambreen Khawar, Elisabeth Eppard, Frank Roesch, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Florian. C. Gaertner, Markus Essler & Ralph. A. Bundschuh. (2019) Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases. Annals of Nuclear Medicine 33:6, pages 404-413.
Crossref
Crossref
Xiao‑Lin Huang, Lie‑Yu Huang, Yu‑Ting Cheng, Fang Li, Qian Zhou, Chao Wu, Qian‑Hui Shi, Zhi‑Zhong Guan, Jian Liao & Wei Hong. (2019) Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. International Journal of Molecular Medicine.
Crossref
Crossref
Ourania Nicolatou-Galitis, Morten Schiødt, Rui Amaral Mendes, Carla Ripamonti, Sally Hope, Lawrence Drudge-Coates, Daniela Niepel & Tim Van den Wyngaert. (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 127:2, pages 117-135.
Crossref
Crossref
Yunlu Cai, Tiantian Gao, Shiping Fu & Ping Sun. (2018) Development of zoledronic acid functionalized hydroxyapatite loaded polymeric nanoparticles for the treatment of osteoporosis. Experimental and Therapeutic Medicine.
Crossref
Crossref
Luca Dalle Carbonare, Monica Mottes, Giovanni Malerba, Antonio Mori, Martina Zaninotto, Mario Plebani, Alessandra Dellantonio & Maria Valenti. (2017) Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients. International Journal of Molecular Sciences 18:6, pages 1261.
Crossref
Crossref
Yiming Tian, Rui Wang, Lianyuan Liu, Chunming Ma, Qiang Lu & Fuzai Yin. (2016) Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
I. Aktas, C. Nazikoglu, A. Kepez, F. U. Ozkan, M. Y. Kaysin, P. Akpinar, Z. Dogan, C. Ileri, S. Saymaz & O. Erdogan. (2016) Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis. Osteoporosis International 27:12, pages 3543-3547.
Crossref
Crossref
Chanchal Kumar, Inusha Panigrahi, Abhishek Somasekhara Aradhya, Babu Lal Meena & Niranjan Khandelwal. (2016)
Zoledronate for
Osteogenesis imperfecta
: evaluation of safety profile in children
. Journal of Pediatric Endocrinology and Metabolism 29:8, pages 947-952.
Crossref
Crossref
Celina Ang. (2016) Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World Journal of Gastroenterology 22:3, pages 906.
Crossref
Crossref
Charles C. Peyton & K. C. Balaji. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
231
257
.
Mitsuhiro Nakamura, Ryogo Umetsu, Junko Abe, Toshinobu Matsui, Natsumi Ueda, Yamato Kato, Sayaka Sasaoka, Kohei Tahara, Hirofumi Takeuchi & Yasutomi Kinosada. (2015) Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. Journal of Pharmaceutical Health Care and Sciences 1:1.
Crossref
Crossref
Victor R. Gordeuk. (2015) Osteoclast activation and sickle bone disease. Blood 126:20, pages 2259-2260.
Crossref
Crossref
Luca Dalle Carbonare, Alessandro Matte’Maria Teresa Valenti, Angela SicilianoAntonio MoriVittorio SchweigerGino Zampieri, Luigi Perbellini & Lucia De Franceschi. (2015) Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. Blood 126:20, pages 2320-2328.
Crossref
Crossref
Joshua D. Maier & Steven N. Levine. (2013) Hypercalcemia in the Intensive Care Unit. Journal of Intensive Care Medicine 30:5, pages 235-252.
Crossref
Crossref
Katri Koivisto, Eero Kyllönen, Marianne Haapea, Jaakko Niinimäki, Kaj Sundqvist, Timo Pehkonen, Seppo Seitsalo, Osmo Tervonen & Jaro Karppinen. (2014) Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging. BMC Musculoskeletal Disorders 15:1.
Crossref
Crossref
Rana R. McKay, Mary-Ellen Taplin & Toni K. Choueiri. (2013) Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer. Hematology/Oncology Clinics of North America 27:6, pages 1261-1283.
Crossref
Crossref
Dipika V. Patel, Anne Horne, Meaghan House, Ian R. Reid & Charles N.J. McGhee. (2013) The Incidence of Acute Anterior Uveitis after Intravenous Zoledronate. Ophthalmology 120:4, pages 773-776.
Crossref
Crossref
Nicole E. Cieri & Stephanie J. Seyse. (2012) Gastrointestinal Bleeding Following Intravenous Ibandronate administration. Journal of Pharmacy Practice 25:3, pages 396-399.
Crossref
Crossref
Hamid Namazi. (2012) Well-Differentiated Hand Liposarcoma with Bone Metastases Treated Successfully with Zoledronic Acid: A Molecular Mechanism. Onkologie 35:5, pages 300-300.
Crossref
Crossref